On transparency, responsibility, and accountability

Clinical Microbiology and Infection

Volumn 15, Issue 12, 2009, Pages 1100-1102

  Paul, M ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Authorship; Randomized controlled trials; Sponsorship

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN;

ACCESS TO INFORMATION; CLINICAL STUDY; DATA ANALYSIS; DRUG MANUFACTURE; DRUG RESEARCH; FUNDING; GOOD CLINICAL PRACTICE; GROUP A STREPTOCOCCAL INFECTION; NOTE; PEER REVIEW; PHARYNGITIS; PRIORITY JOURNAL; PUBLICATION; TONSILLITIS;

EID: 70649107672     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.02820.x     Document Type: Note

References (13)

1. Uniform requirements for manuscripts submitted to biomedical journals. International Committee of Medical Journal Editors. JAMA 1997, 277:927-934.
2. Gotzsche PC, Hrobjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Ghost authorship in industry-initiated randomised trials. PLoS Med 2007, 4:e19.
3. Johansen HK, Gotzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA 1999, 282:1752-1759.
4. Flanagin A, Carey LA, Fontanarosa PB. Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA 1998, 280:222-224.
5. Gotzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database Syst Rev 2002, 2:CD000026.
6. Jorgensen KJ, Gotzsche PC, Johansen HK. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2006, 1:CD004707.
7. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA 2008, 299:1800-1812.
8. Guidance for industry E6 good clinical practice: consolidated guidance 1996, http://www.fda.gov/cder/guidance/959fnl.pdf, US Department of Health and Human Services FaDACfDEaR, Center for Biologics Evaluation and Research, Available at: (last accessed 16 April 2009
9. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
10. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004, 363:1341-1345.
11. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 2007, 7:338-348.
12. Bisno AL, Gerber MA, Gwaltney JM, Kaplan EL, Schwartz RH. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases Society of America. Clin Infect Dis 2002, 35:113-125.
13. Lewis TR, Reichman JH, So AD. The case for public funding and public oversight of clinical trials. Economist's Voice 2007, 4. http://www.bepress.com/cgi/viewcontent.cgi?article=1123&context=ev, Article 3. Available at: (last accessed 27 August 2008